50 results about "Myocardial Contractions" patented technology

Systems and methods according to the invention employ an acceleration sensor to characterize the synchrony or dyssynchrony of the left ventricle. Patterns of acceleration related to myocardial contraction can be used to assess synchrony or dyssynchrony. Time-frequency transforms and coherence are derived from the acceleration. Information and numerical indices determined from the acceleration time frequency transforms and coherence can be used to find the optimal pacing location for cardiac resynchronization therapy. Similarly, the information can be used to optimize timing intervals including V to V and A to V timing.

The invention discloses an intelligent sleep monitoring system with a small contact surface, which is composed of a physiological signal acquisition module, an MCU control module, a power supply module, a sleeping posture adjustment module and an alarm rescue module. Among them, the physiological signal acquisition module uses an air cushion to balance the force generated by the myocardial contraction, chest contraction and other muscle movements during respiration, and converts physiological signals such as human respiration, heart rate, and displacement into electrical signals through pressure sensors. After filtering and amplifying, it is sent to the MCU for processing to determine whether there are abnormalities such as sleep apnea termination, cardiac arrest, and falling. sound and light alarm. The invention has a small contact area with the measured body, does not need to wear sensors, does not affect sleep, has low cost, and is convenient for operation and maintenance management. A sleep monitoring system that can be used for daily home monitoring of old and young.

The present invention relates to 2-arylamino-4-(heterocyclic)aminopyrimidines inhibitors which are inhibitors and therefore inhibit Protein Kinase C-alpha (PKC-α). The PKC-α inhibitors of the present invention are important for improving myocardial intracellular calcium cycling, resulting in improved myocardial contraction and relaxation performance and thereby slowing the progression of heart failure. The present invention further relates to compositions comprising said 2-arylamino-4-(heterocyclic)amino-pyrimidines and to methods for controlling, abating, or otherwise slowing the progression of heart failure.

The present invention relates to 2-arylamino-4-(aminoalkylene)aminopyrimidines inhibitors which are inhibitors and therefore inhibit Protein Kinase C-alpha (PKC-α). The PKC-α inhibitors of the present invention are important for improving myocardial intracellular calcium cycling, resulting in improved myocardial contraction and relaxation performance and thereby slowing the progression of heart failure. The present invention further relates to compositions comprising said 2-arylamino-4-(aminoalkylene)amino-pyrimidines and to methods for controlling, abating, or otherwise slowing the progression of heart failure.

The invention discloses a myocardial excitation contraction coupling time diagnostic apparatus and application thereof. The diagnostic apparatus provided by the invention comprises an electrocardio collection unit, an ultrasonic heartbeat collection unit, an analysis processing unit and a data output unit, wherein the electrocardio collection unit is used for defecting myocardial electrical excitation; the ultrasonic heartbeat collection unit is used for detecting myocardial contraction; the analysis processing unit is used for recording the starting time of the myocardial electrical excitation detected by the electrocardio collection unit and the starting time of the myocardial contraction detected by the ultrasonic heartbeat collection unit and analyzing the time interval between the starting time of the myocardial electrical excitation and the starting time of the myocardial contraction; and the data output unit is used for outputting data obtained by the analysis processing unit. Experiments prove that the coupling delay time of the heart failure patients is markedly longer than that of the healthy volunteers so that the coupling delay time displayed by the diagnostic apparatus disclosed by the invention can be used for evaluating the heart function.

The invention discloses deer heart health wine. A preparation method of the deer heart health wine comprises the following steps: taking a deer heart, ginseng, radix ophiopogonis, schizandra fruits, spina date seeds, platycladi seeds, radish seeds, caulis spatholobi, poria cocos, bighead atractylodes rhizome, liquorice, pawpaw and radix salviae miltiorrhizae, washing and then slicing the traditional Chinese medicines; putting the traditional Chinese medicine slices in pure grain white wine with an alcohol content of 60%, sealing the traditional Chinese medicine slices and wine in a pot and immersing the slices for a plurality of days; simultaneously transferring the immersed traditional Chinese medicine slices and wine into an extraction pot for reduced pressure extraction, filtering the traditional Chinese medicine dregs to obtain traditional Chinese medicine wine; transferring the traditional Chinese medicine wine into a sealing pot for storing for plurality of days to obtain the deer heart health wine. The deer heart health wine has the functions of regulating cardiac rhythm, increasing soluble blood volume, calming heart and nerves, enhancing myocardial contraction force, reinforcing spleen and generating blood, promoting blood circulation to remove blood stasis and clearing and activating the channels and collaterals, and has the health effects on insufficient blood supply to heart and brain, insomnia and amnesia, anemia, infarction of small cardiac blood vessels.

The present direct cardiac compression (DCC) design, termed Cardiac Resynchronization Compression Sac System (CRCSS), combines the mechanical and electrical characteristics associated with DCC and cardiac resynchronization therapy (CRT), respectively. The CRCSS comprises a shell, at least one opening on the shell, at least one inflatable balloon, and a pumping system. The shell is custom manufactured to substantially conform to the contour of a portion of a heart, the contour being obtained by an imaging system. The opening on the shell is designed for passing pericardial fluid so as not to impede the myocardial contraction. The inflatable balloon attaches to at least one predetermined location of the inner surface of the shell. Furthermore, the shell naturally positions in the pericardium space without resorting to any artificial force to prevent it from dislodging from the heart. When the inflatable balloon inflates at least one ventricular free wall of the heart is compressed.